Search results for "tamoxifen"

showing 10 items of 70 documents

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

2006

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGenes BRCA2Genes BRCA1Breast NeoplasmsBreast cancerRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAromataseskin and connective tissue diseasesbiologybusiness.industryIncidence (epidemiology)Estrogen AntagonistsHematologymedicine.diseaseClinical trialTamoxifenOncologyChemotherapy AdjuvantRelative riskbiology.proteinHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugAnnals of Oncology
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

Tamoxifen-loaded polymeric micelles: preparation, physico-chemical characterization and in vitro evaluation studies.

2004

Several samples of polymeric micelles, formed by amphiphilic derivatives of PHEA, obtained by grafting into polymeric backbone of PEGs and/or hexadecylamine groups (PHEA-PEG-C(16) and PHEA-C(16)) and containing different amount of Tamoxifen, were prepared. All Tamoxifen-loaded polymeric micelles showed to increase drug water solubility. TEM studies provided evidence of the formation of supramolecular core/shell architectures containing drug, in the nanoscopic range and with spherical shape. Samples with different amount of encapsulated Tamoxifen were subjected to in vitro cytotoxic studies in order to evaluate the effect of Tamoxifen micellization on cell growth inhibition. All samples of T…

Polymers and PlasticsAntineoplastic Agents HormonalPolymersSupramolecular chemistryBioengineeringMicellePolyethylene GlycolsBiomaterialsPlasmaDrug Delivery SystemsTamoxifen polymeric micelles polyaspartammideAmphiphileMaterials ChemistryOrganic chemistryHumansMicellesAqueous solutionMolecular StructureChemistryHydrogen-Ion ConcentrationTamoxifenMembraneSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryLiberationDrug carrierPeptidesBiotechnologyNuclear chemistryMacromolecular bioscience
researchProduct

in vitro biological evaluation of folate-functionalized block copolymer micelles for selective anti-cancer drug delivery.

2008

The main objective of this study was to evaluate the ability of folic acid-functionalized diblock copolymer micelles to improve the delivery and uptake of two poorly water-soluble anti-tumor drugs, tamoxifen and paclitaxel, to cancer cells through folate receptor targeting. The diblock copolymer used in this study comprised a hydrophilic poly[2-(methacryloyloxy)ethyl phosphorylcholine] (MPC) block, carrying at the chain end the folate targeting moiety, and a pH-sensitive hydrophobic poly[2-(diisopropylamino)ethyl methacrylate] (DPA) block (FA-MPC-DPA). The drug-loading capacities of tamoxifen- and paclitaxel-loaded micelles were determined by high performance liquid chromatography and the m…

Polymers and PlasticsPaclitaxelPhosphorylcholineBioengineeringMicelleBiomaterialsDrug Delivery SystemsFolic AcidPolymethacrylic AcidsPolymer chemistryBLOCK COPOLYMERS MICELLES DRUG DELIVERYMaterials ChemistryHumansCytotoxicityMicellesPhosphorylcholineChemistryAntineoplastic Agents PhytogenicEnd-groupTamoxifenSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFolate receptorCancer cellBiophysicsCaco-2 CellsDrug carrierK562 CellsFolate targetingBiotechnologyMacromolecular bioscience
researchProduct

Peculiar mechanism of solubilization of a sparingly water soluble drug into polymeric micelles. Kinetic and equilibrium studies.

2012

Complementary kinetic and equilibrium studies on the solubilization process of the sparingly water soluble tamoxifen (TAM) drug in polymeric aqueous solutions have been performed by using the spectrophotometric method. In particular, the amphiphilic copolymers obtained by derivatization of polymeric chain of poly(N-2-hydroxyethyl)-dl-aspartamide, PHEA, with poly(ethylene glycol)s, PEG (2000 or 5000 Da), and/or hexadecylamine chain, C16, namely PHEA-PEG2000-C16, PHEA-PEG5000-C16, PHEA-C16, have been employed. Preliminary to the kinetic and equilibrium data quantitative treatment, the molar absorption coefficient of TAM in polymeric micelle aqueous solution has been determined. By these studi…

PolymersSurface PropertiesKineticsMicellesparingly water soluble drug TAM polymeric micelle kineticchemistry.chemical_compoundReaction rate constantstomatognathic systemMaterials ChemistryCopolymerOrganic chemistryPhysical and Theoretical ChemistrySolubilityParticle SizeMicellesSettore CHIM/02 - Chimica FisicaAqueous solutionWaterBinding constantSurfaces Coatings and FilmsKineticsTamoxifenchemistryChemical engineeringSolubilityEthylene glycolThe journal of physical chemistry. B
researchProduct

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast can…

2010

Introduction Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression and response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype. Methods We defined two independent molecular signatures of the PI3K pathway: a pro…

ProteomeMessengerEstrogen receptorPhosphatidylinositol 3-Kinases0302 clinical medicineReceptorsTumor Cells CulturedInsulin-Like Growth Factor IReceptorCancerOligonucleotide Array Sequence AnalysisMedicine(all)0303 health sciencesCulturedTumorBlottingReverse Transcriptase Polymerase Chain ReactionPrognosis3. Good healthTumor CellsGene Expression Regulation NeoplasticReceptors Estrogen030220 oncology & carcinogenesisFemaleSignal transductionWesternmedicine.drugBiotechnologySignal TransductionResearch Articlemedicine.medical_specialtyBlotting WesternOncology and CarcinogenesisBreast NeoplasmsBiology03 medical and health sciencesInternal medicineProgesterone receptorBreast CancerBiomarkers TumormedicineGeneticsHumansRNA MessengerOncology & CarcinogenesisPI3K/AKT/mTOR pathway030304 developmental biologyCell ProliferationNeoplasticCell growthGene Expression ProfilingEstrogenGene expression profilingEndocrinologyGene Expression RegulationCancer researchRNAProto-Oncogene Proteins c-aktTamoxifenBiomarkersBreast Cancer Research : BCR
researchProduct

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

2008

Abstract Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy–based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor–positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor–positive cancers. Unlike AKT1 mutations that were absent …

ProteomicsCancer ResearchClass I Phosphatidylinositol 3-KinasesAKT1Breast NeoplasmsBiologymedicine.disease_causeArticlePhosphatidylinositol 3-KinasesBreast cancermedicineHumansPTENneoplasmsProtein kinase BPI3K/AKT/mTOR pathwayMutationPTEN PhosphohydrolaseCancerGenomicsmedicine.diseaseOncologyMutationCancer researchbiology.proteinFemaleProto-Oncogene Proteins c-aktCell DivisionTamoxifenmedicine.drugCancer Research
researchProduct

Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expres…

2010

Steatosis is the first step in the development of non-alcoholic fatty liver disease (NAFLD). However, the mechanisms involved in its pathogenesis are not fully understood. Many nuclear receptors (NRs) involved in energy homeostasis and biotransformation constitute a network connecting fatty acids, cholesterol and xenobiotic metabolisms; therefore, multiple NRs and their ligands may play a prominent role in liver fat metabolism and accumulation. In this study we have attempted to gain insight into the relevance of the NR superfamily in NAFLD by investigating the steatogenic potential of 76 different NR ligands in fatty acid overloaded human hepatocytes and hepatoma cells. Moreover, we have d…

Selective Estrogen Receptor ModulatorsIndolesPeroxisome proliferator-activated receptorReceptors Cytoplasmic and NuclearBiologyRetinoid X receptorPhloroglucinolToxicologyLigandsCalcitriol receptorBridged Bicyclo CompoundsPregnenedionesmedicineHumansLiver X receptorVitamin ACells CulturedCalcifediolchemistry.chemical_classificationPregnane X receptorAndrostenolsTerpenesFatty liverFatty acidGeneral MedicineHep G2 Cellsmedicine.diseaseFarnesolFatty LiverPPAR gammaTamoxifenCholesterolNuclear receptorchemistryBiochemistryHepatocytesChemico-biological interactions
researchProduct

Photodegradation of pharmaceutical drugs in aqueous TiO2 suspensions: mechanism and kinetics

2007

WOS: 000251165800003

Settore ING-IND/24 - Principi Di Ingegneria ChimicaAqueous solutionendocrine system diseasesChemistryKineticsInorganic chemistryHeterogeneous PhotocatalysisGeneral ChemistryMineralization (soil science)Heterogeneous catalysisHeterogeneous photocatalysiCatalysischemistry.chemical_compoundTamoxifenTitanium dioxidePhotocatalysisTitanium dioxidePartial oxidationGemfibrozilPhotodegradationDrug photodegradation
researchProduct

Comparison of Prognostic Signatures in Node-Negative Tamoxifen-Treated Breast Cancer Patients.

2009

Abstract Background: A number of molecular signatures have been published to aid breast cancer prognosis and therapy response prediction. A 76-gene signature has been developed in a node-negative patient cohort that did not receive systemic therapy.1 Another prognostic 97-gene signature measures predominantly proliferation-associated genes.2 Finally, a 21-gene signature has been developed for node-negative and estrogen receptor–positive breast cancer patients treated with tamoxifen in the adjuvant setting.3 Here we compare the prognostic performance of all three published algorithms in a cohort of 189 node-negative breast cancer patients treated with tamoxifen.Materials and Methods: Fresh-f…

Subset AnalysisOncologyCancer Researchmedicine.medical_specialtyProportional hazards modelbusiness.industryCancermedicine.diseaseBioinformaticsSubclassNode negativeBreast cancerOncologyInternal medicineCohortmedicinebusinessTamoxifenmedicine.drugCancer Research
researchProduct